Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montano, M
Right arrow Articles by Selman, M
Right arrow Search for Related Content
PubMed
Right arrow Articles by Montano, M
Right arrow Articles by Selman, M

Chest, Vol 96, 1115-1119, Copyright © 1989 by American College of Chest Physicians

ARTICLES

Lung collagenase inhibitors and spontaneous and latent collagenase activity in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis

M Montano, C Ramos, G Gonzalez, F Vadillo, A Pardo and M Selman
Instituto Nacional de Enfermedades Respiratorias SSA, Mexico City, Mexico.

In order to analyze the mechanisms involved in the decreased collagenolytic activity previously observed in interstitial lung fibrosis, we studied the inhibitory collagenase activity and the latent activable collagenase in lung samples from five patients with IPF, six with HP, and three control subjects. Our results showed that in both diseases, the inhibitor levels were significantly higher than in control subjects. Findings suggest that in IPF low amounts of collagenase plus excessive enzyme-inhibitors may be operating to decrease collagen catabolism. In contrast, HP lungs seem to contain adequate amounts of the enzyme but higher levels of inhibitors play a role in the abnormal degradation observed in some patients.


This article has been cited by other articles:


Home page
 ThoraxHome page
M R Hill, L Briggs, M M Montano, A Estrada, G J Laurent, M Selman, and A Pardo
Promoter variants in tissue inhibitor of metalloproteinase-3 (TIMP-3) protect against susceptibility in pigeon breeders' disease
Thorax, July 1, 2004; 59(7): 586 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Selman, V. Ruiz, S. Cabrera, L. Segura, R. Ramirez, R. Barrios, and A. Pardo
TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?
Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L562 - L574.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
N. Varo, M. J. Iraburu, M. Varela, B. Lopez, J. C. Etayo, and J. Diez
Chronic AT1 Blockade Stimulates Extracellular Collagen Type I Degradation and Reverses Myocardial Fibrosis in Spontaneously Hypertensive Rats
Hypertension, June 1, 2000; 35(6): 1197 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Laviades, N. Varo, J. Fernandez, G. Mayor, M. J. Gil, I. Monreal, and J. Diez
Abnormalities of the Extracellular Degradation of Collagen Type I in Essential Hypertension
Circulation, August 11, 1998; 98(6): 535 - 540.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Chest Physicians.